等待开盘 10-07 09:30:00 美东时间
+0.080
+0.49%
Immutep Limited received an A$856,669 cash rebate from Australia's R&D tax incentive program for eligible activities in 2025. The company also benefits from France's CIR tax incentive and Germany's Forschungszulage program through its subsidiaries. These funds will support R&D for its product candidates, efti and IMP761, with cash flow expected until mid-2028.
09-30 12:00
Pearson (PSO) has agreed to acquire Workera, an AI-powered skills intelligence platform that helps enterprises assess and verify workforce capabilities. The acquisition is expected to close in the sec...
09-29 16:23
Pearson strengthens enterprise offering with adaptive assessment and skills intelligence to meet growing demand for workforce transformation in the era of AI
09-29 16:09
(来源:上观新闻) 今天(24日),在上海举行的2026年世界技能大会上,培生发布最新研究:《共赴万千职业未来:帮助技能、技术及服务型职场新...
09-24 16:15
(来源:上观新闻) 9月22日晚,第48届世界技能大赛在上海正式启幕。世界技能大会作为“一赛两会”的重要组成部分,于9月23日至25日在国家...
09-24 06:40
(来源:上观新闻) 9月22日晚,第48届世界技能大赛在上海开幕。64个比赛项目,从运输与物流、制造与工程技术到创意艺术与时尚,全球年轻人把...
09-23 11:15
Immutep Limited announced a change to its ADS ratio, effective September 28, 2026, to address Nasdaq's minimum bid price requirement. The ratio will change from 1 ADS representing 10 ordinary shares to 1 ADS representing 200 ordinary shares, equivalent to a 1:20 reverse split. This adjustment aims to help the company regain compliance with Nasdaq listing rules, as its ADS bid price fell below $1.00 for 30 consecutive days. The change does not aff...
09-21 12:00
Cue Biopharma announced positive results from its Phase 2 clinical trial of CUE-221 for chronic spontaneous urticaria (CSU), showing significant efficacy and a favorable safety profile. The trial met primary and key secondary endpoints with high statistical significance, demonstrating superior performance compared to XOLAIR. CUE-221's dual mechanism of action, targeting IgE, may offer a fundamental difference in treating IgE-mediated diseases. Th...
09-20 10:00
Pearson (PSO) announced the acquisition of ITS, a Baltimore-based assessment technology provider specializing in the management, delivery, and reporting of testing programs. Financial terms of the dea...
09-18 17:26